Rocket Pharmaceuticals, Inc. RCKT 深 沪
已收盘 10-30 16:00:00 美东时间
2.44
-0.100
-3.94%
华盛通- 最 高2.57
- 今 开2.50
- 成交量 153.50万股
- 最 低 2.37
- 昨 收 2.54
- 总市值 2.68亿
- 52周最高 5.45
- 市盈率 静 --
- 换手率 1.40%
- 52周最低 2.165
- 委 比 -60.21%
- 总股本 1.10亿
- 历史最高 67.48
- 量 比 0.91
- 振 幅 7.87%
- 历史最低 2.165
- 每 手 1
- 风险率 0.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅179.23%！奥本海默上调Aurora Innovation目标价至16美元，维持"跑赢大市"评级
今日重点评级关注：奥本海默：维持Aurora Innovation"跑赢大市"评级，目标价从15美元升至16美元；富国银行：维持Applied Digital"超配"评级，目标价从50美元升至55美元
10-09 16:25
This Palantir Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Goldman Sachs analyst Richard Law upgraded Rocket Pharmaceuticals Inc (NASDAQ:RCKT) from Sell to ...
10-08 20:29
美股大行评级 | 潜在涨幅175.74%！美光科技获DA Davidson上调目标价至3000美元，维持"买入"评级
今日重点评级关注：DA Davidson：维持美光科技"买入"评级，目标价从2100美元升至3000美元；Leerink Partners：维持OmniAb"跑赢大市"评级，目标价从10美元升至12美元
10-08 12:30
Leerink Partners Maintains Market Perform on Rocket Pharmaceuticals, Lowers Price Target to $4
Leerink Partners analyst Roanna Ruiz maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Market Perform and lowers the price target from $7 to $4.
10-08 01:01
Rocket Pharma updates progress on RP-A501 for Danon disease
Rocket Pharmaceuticals (RCKT) said that it has a clear path to complete a pivotal phase 2 trial for its Danon disease asset, RP-A501. The company said 12 male patients will receive treatment. Co-prim...
10-07 23:44
Rocket Pharmaceuticals Secures Hercules Loan to Extend Runway
Rocket Pharmaceuticals ( ($RCKT) ) has issued an update. On September 30, 2026,...
10-07 05:54
美股大行评级 | 矿业股获齐声唱多！金田、纽曼矿业等目标价均获上调；携程遭看淡至60美元，较现价仍溢价5成
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从10.25美元升至11美元；Needham：上调Rocket Pharmaceuticals"买入"评级，目标价9美元
09-17 16:16
Rocket Pharmaceuticals Aligned With FDA on Continued Enrollment and Dosing and key elements of Phase 2 trial of RP-A501 for Danon disease
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited cardiovascular disorders, today announced alignment with the U.S. Food and Drug Administration (FDA) on cont...
09-15 19:12
美股大行评级 | 潜在涨幅207.38%！Truist Securities上调AbCellera Biologics目标价至30美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持AbCellera Biologics"买入"评级，目标价从12美元升至30美元；Stifel：维持Proficient Auto Logistics"买入"评级，目标价从9美元升至12美元
08-12 08:45
Wedbush Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $15
Wedbush analyst Yun Zhong maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and lowers the price target from $16 to $15.
08-11 21:51
